HomeAbout Us

ABOUT USA Bangor University Spin Out, Based On Leading Edge Technology

Established in 2015 as a Point of Care (PoC) diagnostics company to deliver unique devices for the diagnosis of Mycobacterial infections, utilising novel mycolic acid antigens.

Situated within M-SParc, a unique science park that brings together companies of all sizes. Encouraging both innovation and collaboration, within high-spec laboratories and a friendly environment.

CORE TECHNOLOGYFully Synthetic Mycolic Acids

Unique compounds that are potent and selective signalling agents in the immune system

Mycolic acids are unique to mycobacteria and responsible for many of their properties.

Synthetic mycolic acids and other cell wall components of mycobacteria are useful in a number of areas including:

  • Diagnostic Testing
  • Vaccine Adjuvants
  • Prophylactic and therapeutic agents
  • Asthma Treatment
  • Anti-cancer Agents

OUR TEAMA small but dedicated team of scientists

https://diagnostig.com/wp-content/uploads/2021/02/mark.jpg

Prof. Mark Baird

Managing Director
https://diagnostig.com/wp-content/uploads/2021/02/malcolm.jpg
CHAIRMAN, IP MANAGERDr. Malcolm Jones
https://diagnostig.com/wp-content/uploads/2021/02/don.jpg
CHIEF COMMERCIAL OFFICERDr. Don Cardy
https://diagnostig.com/wp-content/uploads/2021/02/avatar.jpeg
CORPORATE DIRECTORDr. Garry Reid
https://diagnostig.com/wp-content/uploads/2020/11/dafydd.jpg
RESEARCH AND DEVELOPMENT SCIENTISTDr. Dafydd Thomas
https://diagnostig.com/wp-content/uploads/2020/11/deiniol.jpg
RESEARCH AND DEVELOPMENT SCIENTISTDr. Deiniol Thomas
https://diagnostig.com/wp-content/uploads/2020/11/anna.jpg
RESEARCH AND DEVELOPMENT SCIENTISTAnna Cervi
https://diagnostig.com/wp-content/uploads/2021/02/paul-1.jpg
RESEARCH AND DEVELOPMENT SCIENTISTPaul Mason